anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ETHNOPHARMACOLOGICAL RELEVANCE: Erythrina velutina Willd., commonly known as "mulungu" in Brazil, is a leguminous tree with various traditional medicinal uses. These uses include treating insomnia, central nervous system disorders, convulsions, nervous cough, and inflammation.
AIM OF THE REVIEW: This review aims to comprehensively summarize the ethnomedicinal uses, chemical constituents, pharmacology, and toxicology of E. velutina to explore its potential as a source for new therapeutic agents.
MATERIALS AND METHODS: Information was collected from scientific databases, dissertations, and books. Chemical structures were generated using ChemDraw. To ensure the accuracy of the plant names, "World Flora Online" (www.worldfloraonline.org) was consulted for the accepted names of plants.
RESULTS: E. velutina is indigenous to Brazil, Peru, Ecuador, Colombia, Venezuela, and Hispaniola. Approximately 244 compounds, mainly alkaloids and flavonoids, have been isolated from it. The plant and its extracts have exhibited various bioactivities, such as anti-inflammatory, anxiolytic, anticonvulsant, neuroprotective, analgesic, antimicrobial, and antioxidant effects, validating some of its traditional medicinal uses. Erythrina velutina shows promising therapeutic potential for conditions like convulsion, central nervous disorders, anxiety, insomnia, and inflammation, primarily due to its alkaloid and flavonoid content.
CONCLUSION: The traditional medicinal uses of the plant, combined with modern scientific research, underscore its pharmacological potential. This makes it a significant candidate for drug development. Further research should focus on conducting toxicological studies, clinical trials, and mechanistic investigations. These efforts will enable a comprehensive exploration of its pharmacological properties and potential applications in drug development.
PURPOSE:A thrombus solubilizer comprising an aqueous extract of animal belonging to the family GOKAI (Nereis japonica) or ISOME (Eunice viridis) as an active ingredient. CONSTITUTION:Groud material of animal belonging to the family GOKAI (Nereis japonica) (e.g., perinereis brevicirris, Tylorrhynchus heterochaetus, etc.) or ISOME (e.g., Eunice viridis) (e.g., Eunice aphroditois, marphysa sanguinea, Diopatra sugokai Izuka, AKAMUSHI, etc.) is blended with water, allowed to stand, its supernatant liquid is collected, an aqueous extract of animal belonging to the family GOKAIKA (Nereis japonica) or ISOME (Eunice viridis) is isolated by adding a salt such as ammonium sulfate, etc., to the supernatant liquid, by adding an organic solvent such as an alcohol, etc., to precipitate it, by concentrating the supernatant liquid by the use of an ultrafiltration, and lopphilizing it, and fractionated and purified by using ion exchange chromatography, etc. The extract shows improved thrombus solubilizing ability by oral administration, low toxicity and no side effects. The raw material can be fed stably.
OBJECTIVE: Extravasation of infused drugs is not a rare problem in medical practice. Acyclovir is a vesicant and an antiviral medication commonly used for young children. In the present study, we presented a neonate with soft tissue damage due to acyclovir extravasation.
CASE REPORT: A female newborn (Iranian, Asian) with gestational age 37+2 weeks and breech presentation was born by Cesarean delivery from a mother with a recent history of Herpes simplex virus (HSV) infection (Yas Women's Hospital, Tehran, Iran). Intravenous administration of acyclovir was initiated through a peripheral catheter inserted on the dorsal side of the left hand. A few minutes after the second dose, the patient showed a diffused firm swelling, local discoloration, and induration in the dorsum of the hand. The peripheral catheter was removed immediately. Hyaluronidase was injected subcutaneously in five different regions around the catheterization site. Intermittent limb elevation and cold compression (for 10 minutes) were applied. Serial follow-ups and examinations were performed hourly to check limb inflammation, ischemia, and compartment syndrome. The limb swelling and discoloration significantly improved 4 hours after the second dose of hyaluronidase.
CONCLUSION: Early diagnosis of acyclovir extravasation and immediate management could prevent severe complications in neonates. Further studies are needed to suggest a standard approach and treatment protocol for acyclovir extravasation.
FIELD: pharmacy. SUBSTANCE: method of preparing solid pharmaceutical compositions containing L-3,4-dihydroxyphenylalanine and L-α-hydrazino-a-methyl-3,4-dihydroxyphenylpropionic acid at their mass ratio = (3.5-10):1, respectively, involves the following stages: the indicated active components were milled with lactose and/or microcrystalline cellulose taken at amount 20-33% of composition mass and mixed if necessary with dyeing agent. The obtained mixture is treated with stearin at amount 1.5-2% of composition mass dissolved in aliphatic alcohol containing 2-4 carbon atoms, dried, granulated and then dried granulate is mixed if necessary with special additions and pressed to make tablets. The latter have 55-70% active components by mass. Also, film coating can be applied on tablet surface. EFFECT: improved method of composition making. 2 cl, 1 tbl
The invention discloses a lactic acid-based polymer disc-shaped drug-loaded particle, a sustained-release preparation and a preparation method thereof. Polylactic-co-glycolic acid (PLGA) disc-shaped microparticles were prepared by an emulsion-solvent evaporation method. PLGA is used as a raw material, and hydrophobic drugs are entrapped: simvastatin, azithromycin, FK-506; or a hydrophilic drug: BSA. The mass ratio of the drug to the lactic acid-based polymer high molecular material is 1: 5-20. BSA drug-loaded particles are prepared, and simvastatin drug-loaded particles are prepared and subjected to in vitro drug release evaluation. The results show that the preparation method is novel, has good reproducibility, improves the drug loading rate and the encapsulation rate, and has good slow release effect. The novel carrier and the preparation have potential industrial production value in the fields of local administration and drug sustained release.
BACKGROUND: Human papillomavirus (HPV) is causally linked to oropharyngeal squamous cell carcinoma (OPSCC). Testing for plasma tumor tissue modified viral (TTMV)-HPV DNA has emerged as a biomarker strategy for post-treatment surveillance to identify recurrent disease. We aimed to understand the prognostic and predictive potential of TTMV-HPV DNA when monitoring patients who had developed recurrent or metastatic (R/M) HPV+OPSCC.
METHODS: This retrospective observational cohort study included 80 patients from 4 academic centers with R/M HPV+OPSCC if they had ≥ 1 plasma TTMV-HPV DNA test obtained at any point during their R/M disease course. Physician-reported clinical data and treatment history were captured in a centralized database, along with investigator-assessed response to therapy and survival. Descriptive statistics and non-parametric tests of association were employed along with survival analyses (Kaplan-Meier method).
RESULTS: Sixteen (20 %) patients had ≥ 5 test results over time. Consecutive TTMV-HPV DNA tests were performed a median of 73 days apart. Median TTMV-HPV DNA scores were higher with an increasing per-patient number of metastatic sites (<2 vs. 2+; p < 0.01). Score changes over time were influenced by R/M treatment modality and became undetectable in 67 % (12/18) of patients who achieved a complete response to R/M therapy. Patients with detectable scores at last follow-up had significantly worse survival compared with those who were undetectable (log-rank test, p < 0.01).
CONCLUSIONS: TTMV-HPV DNA appears useful as a prognostic tool for monitoring response to therapy in the R/M setting. In the future, TTMV-HPV DNA could be explored as an exploratory clinical trial endpoint in the metastatic setting.
Systems, methods, and apparatus for diabetes management include a portable diabetes management system (DMS) device. The DMS device includes a processor, a data storage device, a touchscreen display, and wireless communications facilities. An interactive display screen configured to be displayed on the touchscreen display lists a selectable subset of a plurality of different detected patterns related to blood glucose measurement data received by the DMS device. The patterns are detected based on a plurality of algorithms executable on the processor. A subset of detected patterns is determined based upon a frequency with which the patterns are detected and a priority is assigned to the detected patterns. Numerous other aspects are provided.
The invention relates to a method to reduce the influence of negative sensation phenomena (NSP) caused by neuropathy. NSP are reduced abilities to sense slight touch, ache, proprioception, vibration, warmness or hotness, coolness or coldness. NSP are treated with anaesthetic. The anaesthetic is preferably anaesthetic based on benzoic acid. Specifically, patch containing about five percent xylocaine can be used. The anaesthetic is delivered to sufferers of NSP at the positions near the negative sensation phenomena in a transdermal way.
Warm-up, lumbar mobilization, stretching and relaxation. 3x-week (9 weeks), indoor pool, 32o.C/89.6o.F.
The investigators will conduct a cluster-randomized controlled trial of the Malkia Klabu intervention in 40 health facility catchment areas (n=60-70 intervention drug shops; \~3-4 drug shops per area) in the Shinyanga and Mwanza regions of Tanzania, plus a mixed-methods, implementation science study to pinpoint supply-side factors influencing effectiveness (e.g., implementation models, intervention fidelity, shop characteristics).

Malkia Klabu is a loyalty card program derived from a youth participatory process with human centered design. Young women earn punches on the Malkia Klabu loyalty card when they make drug shop purchases that upon accrual can be used towards prizes of increasing value. When joining, young women receive a free HIV self test kit (HIVST) as an opt out sign-up gift, are invited to interact with a physical display of sexual and reproductive health products, including HIVST, and may elect to view videos on a tablet computer about the program, HIVST, and contraception. The back of the card displays discreet symbols representing sensitive products available at the shop (e.g., HIVST, oral contraception). Club members can ask for or point to the product that they want on the card and receive it for free in a discreet bag. Referrals are provided to youth-friendly services at a nearby catchment area health facility for HIV testing, treatment and care, and/or contraception.
All patients treated with opioids, including EXALGO, require careful monitoring for signs of abuse and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use.

Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving.

"Drug-seeking" behavior is very common to addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated claims of loss of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). “Doctor shopping” (visiting multiple prescribers) to obtain additional prescriptions is common among drug abusers, people suffering from untreated addiction and criminals seeking drugs to sell.

Abuse and addiction are separate and distinct from physical dependence and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. Since EXALGO may be diverted for non-medical use, careful record-keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.

Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.

EXALGO is intended for oral use only. Misuse or abuse by breaking, crushing, chewing, or dissolving EXALGO poses a hazard of overdose and death. This risk is increased with concurrent abuse of EXALGO with alcohol and other substances.

With intravenous abuse, the tablet excipients, especially polyethylene oxide, can be expected to result in necrosis and inflammation of cardiac tissues. In addition, parenteral drug abuse is commonly associated with transmission of infectious disease such as hepatitis and HIV.

Healthcare professionals should contact their State Professional Licensing Board or State Controlled Substances Authority for information on how to prevent and detect abuse or diversion of this product.
The invention belongs to the field of biology technology and medicine, and discloses a new human epididymis expression sperm binding protein HEL-122 as well as preparation and application thereof. The invention discloses an amino acid sequence of the HEL-122 protein and provides a recombination expression vector carrying a DNA sequence for coding the protein. The invention also discloses the preparation of the protein and a method for detecting the biology function of the HEL-122 protein. The protein is specifically expressed in the epididymis, and the expression quantity is highest in the epididymis part, and the protein is bound to the equator of the sperm to play a significant role in sperm fertilization. The HEL-122 protein can be used as a targeted protein for researching immunity contraceptives, and clinically diagnosing and treating male infertility. A corresponding gene or protein detection method developed based on the HEL-122 protein can be widely applied to the field of reproductive medicine research.
Neuropathic pain, a debilitating condition, remains a significant challenge due to the lack of effective therapeutic solutions. This study aimed to evaluate the potential of mesenchymal stromal cell (MSC)-derived conditioned medium in alleviating neuropathic pain induced by sciatic nerve compression injury in adult male rats. Forty Wistar rats were randomly assigned to four groups: control, nerve injury, nerve injury with intra-neural injection of conditioned medium, and nerve injury with intra-neural injection of culture medium. Following sciatic nerve compression, the respective groups received either 10 µl of conditioned medium from amniotic fluid-derived stem cells or an equal volume of control culture medium. Behavioral tests for cold allodynia, mechanical allodynia, and thermal hyperalgesia were conducted, and the spinal cord was analyzed using Western Blot and oxidative stress assays. The behavioral experiments showed a decrease in mechanical hyperalgesia and cold allodynia in the group receiving conditioned medium compared to the injury group and the control medium group. Western blot data revealed a decrease in the expression of the CCL2 protein and an increase in GAD65. Oxidative stress tests also showed increased levels of SOD and glutathione in conditioned media-treated animals compared to animals with nerve injury. The findings suggest that conditioned medium derived from amniotic fluid-derived stem cells can effectively reduce neuropathic pain, potentially through the provision of supportive factors that mitigate oxidative stress and inflammation in the spinal cord.
BACKGROUND: Remote secondary neurodegeneration is associated with poststroke cognitive impairment (PSCI). Dl-3-n-butylphthalide (NBP) improves PSCI clinically. However, whether it ameliorates PSCI by alleviating secondary neurodegeneration remains uncertain. Nonhuman primates provide more relevant models than rodents for human stroke and PSCI. This study investigated the effects of NBP on PSCI and secondary neurodegeneration in cynomolgus monkeys after permanent left middle cerebral artery occlusion (MCAO).
METHODS: Thirteen adult male cynomolgus monkeys were randomly assigned to sham (n=4), MCAO+placebo (n=5), and MCAO+NBP groups (n=4). The MCAO+placebo and MCAO+NBP groups received saline and NBP injections intravenously, respectively, starting at 6-hour postsurgery for 2 weeks, followed by soybean oil and NBP orally, respectively, for 10 weeks after MCAO. Infarct size was assessed at week 4 by magnetic resonance imaging. Working memory and executive function were evaluated dynamically using the delayed response task and object retrieval detour task, respectively. Neuron loss, glia proliferation, and neuroinflammation in the ipsilateral dorsal lateral prefrontal cortex, thalamus, and hippocampus were analyzed by immunostaining 12 weeks after MCAO.
RESULTS: Infarcts were located in the left middle cerebral artery region, apart from the ipsilateral dorsal lateral prefrontal cortex, thalamus, or hippocampus, with no significant difference between the MCAO+placebo and MCAO+NBP group. Higher success in delayed response task was achieved at weeks 4, 8, and 12 after NBP compared with placebo treatments (P<0.05), but not in the object retrieval detour task (all P>0.05). More neurons and less microglia, astrocytes, CD68-positive microglia, tumor necrosis factor-α, and inducible NO synthase were observed in the ipsilateral dorsal lateral prefrontal cortex and thalamus after 12 weeks of NBP treatment (P<0.05), but not in the hippocampus (P>0.05).
CONCLUSIONS: Our findings indicate that NBP improves working memory by alleviating remote secondary neurodegeneration and neuroinflammation in the ipsilateral dorsal lateral prefrontal cortex and thalamus after MCAO in cynomolgus monkeys.
FIELD: food industry. SUBSTANCE: food additive contains natural polyvitamins, macro- and micro-elements; and additionally it has autolysates from natural food raw material in the amount of 28.0-70.0 mas.%. Used as biologically-active additive is adaptogenes and/or detoxicants in the amount from 0.5 to 70.0 mas.%. Adaptogenes of vegetable and/or animal origin are used as adaptogenes. Biologically-active additive may additionally contain apiculture products and binding substances. Biologically-active additive may be applied at pyo-septic infection of any localization. EFFECT: increased resistance of organism to any unfavorable environmental factors. 8 cl
<P>PROBLEM TO BE SOLVED: To provide drug-containing micro-particles having a small particle diameter and effectively inhibiting bitterness and controlling elution properties of the drug even when the coating amount is small and to provide a method for producing the micro-particles.  <P>SOLUTION: The drug-containing micro-particles having 10-100 μm average particle diameter are produced by coating drug particles having 1-25 μm average particle diameter during flowing with a coating liquid containing a water-insoluble polymer with 10-50 μm average mist diameter under 0.1-0.3 MPa spray pressure. Cellulose ethers and acrylic acid-based copolymers can be used as the water-insoluble polymer. The spraying ratio of the coating liquid based on 100 pts.wt. of the drug particles is 0.02-0.6 pt.wt./min converted into solid contents.  <P>COPYRIGHT: (C)2008,JPO&INPIT
All subjects will receive LHRH agonist/antagonist per dosage and route of administration specified by the treating physician. Bicalutamide, 50mg, PO will be administered daily. Cycles will be 28 days.
VICTOZA contains liraglutide, an analog of human GLP-1 and acts as a GLP-1 receptor agonist. The peptide precursor of liraglutide, produced by a process that includes expression of recombinant DNA in Saccharomyces cerevisiae, has been engineered to be 97% homologous to native human GLP-1 by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. The molecular formula of liraglutide is C172H265N43O51 and the molecular weight is 3751.2 Daltons. The structural formula (Figure 1) is:

Figure 1 Structural Formula of liraglutide 

VICTOZA injection is a sterile, aqueous, clear, colorless or almost colorless solution for subcutaneous use. Each 1 mL of VICTOZA solution contains 6 mg of liraglutide and the following inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection. VICTOZA has a pH of approximately 8.15, hydrochloric acid or sodium hydroxide may be added to adjust pH. Each pre-filled pen contains a 3 mL solution of VICTOZA equivalent to 18 mg liraglutide (free-base, anhydrous).
There is increasing evidence that a circadian rhythm of feeding (cyclic feeding) could be beneficial for critical ill patients. Cyclic feeding and fasting are assumed to have positive effects on the gut microbiome resulting in optimization of host responses to gastrointestinal pathogens. Another positive effect of cyclic feeding potentially results from activation of a "fasting response", inducing repair pathways such as ketogenesis, mitochondrial biogenesis, anti-inflammatory pathways, antioxidant defenses and autophagy processes. The activation of these repair pathways could diminish cellular stress and promote cellular recovery in critical ill patients. A randomized controlled trial by van Dyck et al. could show that fasting-mimicking intervals of 12 hours are sufficient to generate a metabolic fasting response without risking a caloric deficit. This fasting response can be enhanced by additional supplementation of exogenous ketones. A cyclic enteral nutrition with 12 hours of daytime feeding and 12 hours of ketogenic nighttime fasting compared to a continuous enteral feeding for 24 hours can potentially improve the reconstitution of critically ill Intensive Care patients. This improved reconstitution can be measured by maintenance of muscle mass (measured by ultrasound of the musculus rectus femoris), urea/creatinine ration, length of ventilation, length of ICU and hospital stay, 30-day mortality, ICU mobility scale.